Publications

  1. Sydora B, Wilke M, Ghoshh M, Vine D. (2025). The Impact of the Covid-19 Pandemic on Health and Health Care Experience in those living with Polycystic Ovary Syndrome. International Journal of Women’s Health.
    2025 Feb 4:17:287-298.  doi: 10.2147/IJWH.S504439
  2. Wu E, Wilke M, Raggi P, Becher H, Windram J, Proctor S, Ghosh M, Cree M, Vine D. (2025). ApoB-Remnant-Cholesterol Dyslipidemia, Atherosclerotic Cardiovascular Disease and Cardiac Dysfunction is Exacerbated in Young High-Risk Women with Obesity and Polycystic Ovary Syndrome:a pilot study. Frontiers in Endocrinology: A Lifecourse Perspective on Polycystic Ovary Syndrome (PCOS): Bridging Gaps in Research and Practice (in press)
  3. Hu S, Lalonde-Bester S, Salem J, Koshy S, Vine D, Harrison TG, Yamamoto JM, Benham JL. Validity of administrative health data case definitions for identifying polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2025. Online ahead of print.  DOI: 10.1093/humrep/deaf094
  4. Lalonde-Bester S, Malik M, Sidhu S, Ng K, Masoumi M, Ghosh M, Vine D,. (2024). Prevalence and Etiology of Eating Disorders in Polycystic Ovary Syndrome: A Scoping Review. Advances in Nutrition. 15(4): 1-15. Proctor S, Wang M, Vine D, Raggi P. (2024). Predictive Utility of Remnant Cholesterol in Atherosclerotic Cardiovascular Disease. Current Opinion in Lipidology. 39(4): 300-307. doi.org/10.1016/j.advnut.2024.100193
  5. Vine DF, Wang T, Bakal J and Ghosh M. (2024). Increased Prevalence of Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: a Canadian Population Cohort Study.Can J Cardiol. Special Issue: Why Her Heart Matters: Evidence-Based Practice and Practice-Based Evidence. 6: 314-326.  DOI: 10.1016/j.cjco.2023.12.010
  6. Soto Y, Hernandez A, Sarduy R, Brito V, Marleau S, Vine D, Vazquez AM, Proctor S. (2024). Monoclonal antibody chP3R99 reduces subendothelial retention of atherogenic lipoproteins in Insulin-Resistant rats: Acute treatment versus long-term protection as an idiotypic vaccine for atherosclerosis. Journal of American Heart Association. 2024 Jul 2;13(13):e032419. doi: 10.1161/JAHA.123.032419
  7. Navarese  E, Vine D, Proctor S, Grzelakowska K, Berti S, Kubika J and Raggi P. (2023). Independent Causal Effect of Remnant Cholesterol on Atherosclerotic Cardiovascular Outcomes: a Mendelian randomization study. Arterioscler Thromb Vasc Biol. 2023 Sep;43(9):e373-e380. doi: 10.1161/ATVBAHA.123.319297 
  8. Vine D, Ghosh M, Wang T, Bakal J.  Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome:  a Canadian Population Cohort.  CJC Open. 2023 Dec 16;6(2Part B):314-326.  doi: 10.1016/j.cjco.2023.12.010
  9. Sydora B, Wilke M, Ghosh M, Vine D. Challenges in diagnosis and health care in Polycystic Ovary Syndrome in Canada: a patient view to improve health care.  BMC Women’s Health.   2023 Nov 4;23(1):569. doi.org/10.1186/s12905-023-02732-2.
  10. Donna Vine, Ethan Proctor, Olivia Weaver, Mahua Ghosh, Katerina Maximova, Spencer Proctor.  (2021).  A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome.  Journal of the Endocrine Society, Volume 5, Issue 9,  bvab114.   doi: 10.1210/jendso/bvab114.
  11. Vine DF, Beilin LJ, Burrows S, Huang R-C, Hickey M, Hart R, Proctor S, Mori TA. (2020).  ApoB48-Lipoprotein Remnants Are Associated with Increased Plasma Triglycerides and Cardiometabolic Risk Factors in Adolescents with and without Polycystic Ovary Syndrome. J Endocrinology Society, 4 (8):1-12. doi: 10.1210/jendso/bvaa061.
  12. Vine DF, Wang Y, Jetha MM , Ball GDC, Proctor SD. (2017). Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents with Polycystic Ovary Syndrome. Journal Clinical Endocrinology and Metabolism. 102(3): 970-982. doi: 10.1210/jc.2016-2854.
  13. Krysa J, Vine D, Beilin L, Burrow S, Huan R-C, Mori T, Proctor S. (2020). ApoB48-Lipoprotein Remnants Are Associated with Increased Cardiometabolic Risk in Adolescents. Atherosclerosis. 10: 1602-1612. doi: 10.1016/j.atherosclerosis.2020.04.021.
  14. Kupreeva M, Diane A*, Lehner R, Watts R, Ghosh M, Proctor S, Vine DF. (2019). Metformin and Flutamide Differentially Modulate Insulin-Glucose, Lipid and Apo-B Lipoprotein Metabolism, and Reproductive-Endocrine Function in a PCOS-prone rodent model. Am J Physiol: Endocrinol and Metab. 316(1): E16-33. doi: 10.1152/ajpendo.00018.2018.
  15. Diané A, Kupreeva M, Proctor SD, Pierce WD, Vine DF. (2015). Cardiometabolic and reproductive benefits of early dietary energy restriction and voluntary exercise in an obese PCOS-prone rodent model. Journal of Endocrinology. 226(3): 193-206. doi: 0.1530/JOE-14-0711
  16. Vine DF, Shi D, Wang F, Proctor D. (2014). Insulin and Testosterone are associated with elevated intestinal secretion of lipids and lipoproteins in a rodent model of the metabolic and polycystic ovary syndrome. Journal of Diabetes and Metabolism. 5: 391-399. doi: 10.4172/2155-6156.1000391.
  17. Wang Y, Pendlebury C, Dodd MM, Maximova K, Vine DF, Jetha MM, Ball GD, Proctor SD. (2013). Elevated remnant lipoproteins may increase subclinical CVD risk in pre-pubertal children with obesity: a case- control study. Pediatric Obesity. 8(5): 376-84. doi: 10.1111/j.2047-6310.2012.00116.x.
  18. Shi D and Vine DF. Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Reproductive Biology. 2012 Jul;98(1):185-93. doi: 10.1016/j.fertnstert.2012.04.006.
  19. Shi D, Dyck M, Uwiera R, Russell J, Proctor S, Vine DF (2009). A Unique Rodent Model of Cardiometabolic Risk Associated with the Metabolic and Polycystic Ovary Syndrome. Endocrinology.  Vol. 150, No. 9 4425-4436, Sep 2009. doi: 10.1210/en.2008-1612.

For all Dr. Vine’s other publications, please visit the Metabolic and Cardiovascular Diseases Laboratory website:  Publications – Metabolic and Cardiovascular Diseases Laboratory